Media Center
Cochlear is the global leader in implantable hearing solutions with products including cochlear implants, bone conduction implants and active osseointergrated steady state implants.
Asia Pacific is the home of Cochlear implant technology. Four of Cochlear’s six global manufacturing sites are located in the Asia Pacific region and the multi-channel cochlear implant was invented by Laureate Professor Graeme Clark AC in Melbourne, Australia in 1978. Cochlear has offices in markets across the Asia Pacific region, including operations in Australia, China, Hong Kong, India, Japan, Korea, Malaysia, New Zealand, and Singapore.
Use of Media Center image(s) permitted with the following statement of attribution: Image courtesy of Cochlear Limited.
Media Contact
For all media enquiries, please contact:
Hayley Pentermann
Senior PR Manager, Cochlear Asia Pacific
+61 498 021 795
hpentermann@cochlear.com
Non-media Inquiries
Disclaimer
Please seek advice from your health professional about treatments for hearing loss. Outcomes may vary, and your health professional will advise you about the factors which could affect your outcome. Always follow the directions for use. Not all products are available in all countries. Please contact your local Cochlear representative for product information. Views expressed are those of the individual. Consult your health professional to determine if you are a candidate for Cochlear technology.
For a full list of Cochlear’s trademarks, please visit our Terms of Use page.
In Australia, Cochlear™ Nucleus® implant systems are intended for the treatment of moderately severe to profound hearing loss.
In Australia, Baha® bone conduction implant systems are intended for the treatment of moderate to profound hearing loss.
In Australia, the Cochlear™ Osia® System is indicated for patients with conductive, mixed hearing loss and single-sided sensorineural deafness (SSD) aged 5 years and above with up to 55 decibels sensorineural hearing loss. Patients should have sufficient bone quality and quantity to support successful implant placement. Surgery is required to use this product. Any surgical procedure carries risk.
For Cochlear™ Nucleus®, Osia® and Baha® systems: This product is not available for purchase by the general public. For information on funding and reimbursement please contact your health care professional.
Any testimonial featured on this website is not intended for a New Zealand audience; it is intended for an Australian audience only.
Cochlear implants are available to eligible Australians through the public health system and private health insurance companies.*
Cochlear implants are available to eligible New Zealanders through the public health system (incl. Northern Cochlear Implant Programme and Southern Cochlear Implant Programme) and some private health insurance companies.*
* Conditions and eligibility criteria apply. Please speak to your health insurer and/or healthcare professional to confirm your coverage.